Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tenofovir DF · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | 2 drug arm |
| B | ACTIVE_COMPARATOR | 3 drug arm, SOC |
| Name | Type | Description |
|---|---|---|
| Tenofovir DF | DRUG | TDF 300mg QD for 72 wks |
| lopinavir/ritonavir with 2 Nucleoside RTIs | DRUG | LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks |
| Lopinavir/ritonavir | DRUG | - |
| Emtricitabine | DRUG | - |
| Efavirenz | DRUG | - |
| Lamivudine | DRUG | - |
Inclusion Criteria: * HIV positive * \>18 years of age * HIV RNA\> 400 copies/mL * Any CD 4 cell count * Antiretroviral naïve * No acute illness Exclusion Criteria: \-
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Tenofovir DF is used for the treatment of HIV Infection. It is an infectious disease therapy studied in antiretroviral regimens for HIV-infected patients, including treatment-naive adults. The clinical program enrolled 392 participants across completed Phase 2 and Phase 3 studies.
Tenofovir DF is being developed by Abbott Laboratories, which trades under the ticker ABT. Abbott Laboratories sponsored the clinical trials evaluating Tenofovir DF in HIV Infection, including studies combining it with other antiretroviral agents such as lopinavir, ritonavir, and emtricitabine.
Tenofovir DF is in Phase 3 development for HIV Infection. Three clinical trials have been completed, including two Phase 3 studies and one Phase 2 study. No trials are currently active. The studies together enrolled 392 participants and used active-controlled, randomized designs.
Tenofovir DF has been studied in three completed trials: NCT00234910, a Phase 3 study of a simplified two-drug Kaletra regimen versus a Kaletra triple-drug standard of care regimen in treatment-naive HIV-infected patients; NCT00043966, a Phase 3 study of lopinavir, ritonavir, tenofovir, and emtricitabine in antiretroviral-naive subjects; and NCT00038220, a Phase 2 study of ABT-378/ritonavir plus lamivudine, efavirenz, and Tenofovir DF.
Tenofovir DF is an investigational therapy in clinical development for HIV Infection, with Phase 3 trials completed. The available information does not indicate FDA approval status. It has been evaluated in randomized, active-controlled studies, including combination regimens with other antiretroviral agents.